The Freestyle Libre 3 is the latest continuous glucose monitoring (CGM) system from Abbott. As the next-generation version of the popular Freestyle Libre line, the Libre 3 builds upon the technology and capabilities of the previous Libre and Libre 2 models.
Table of Contents
The Libre 3 represents an exciting advancement in CGM technology from Abbott, building upon the immense success and popularity of the Libre line. With notable upgrades like optional alarms and enhanced accuracy, the Libre 3 provides an improved CGM experience while maintaining the affordability and accessibility that has made Abbott a leader in this category.
The Freestyle Libre 3 is the latest continuous glucose monitoring (CGM) system released by Abbott. It builds upon the hugely popular Libre 2 system with some key enhancements:
The Libre 3 builds on the simplicity and accessibility of previous Libre versions while closing the functionality gap compared to competitors. The extended sensor life and lack of fingersticks are particular highlights for many users. It promises to be the most advanced and user-friendly Libre version yet upon its full launch.
The new Freestyle Libre 3 price is expected to have a similar retail as the previous Libre 2 model. The Libre 2 currently costs around $75-80 for a single 14-day sensor or $290 for a month’s supply of sensors.
Based on past pricing, it’s likely the Libre 3 will launch at the same price point. Abbott has not officially announced pricing yet, but they aim to keep it affordable compared to competitor CGM systems.
Some deals and discounts may be available for the Libre 3:
So in summary, expect the Libre 3 to launch around $75 per sensor, with possible discounts or insurance coverage lowering costs for many users. Abbott tries to make the Libre as affordable as possible to get the benefits of CGM technology to more people.
The Freestyle Libre 3 offers notable cost savings compared to other continuous glucose monitoring (CGM) systems like Dexcom and Medtronic.
The latest Dexcom G7 model has a retail price of around $400 per month without insurance. Medtronic’s Guardian CGM similarly costs $350-400 per month.
In contrast, the Freestyle Libre 3 has a retail monthly price of only $75 without insurance. This represents nearly an 80% discount compared to Dexcom and Medtronic CGMs.
The low cost of the Libre 3 comes from it being a “flash” glucose monitoring system that doesn’t require disposable sensors or transmitters like traditional CGMs. The quarterly sensor can be scanned to get glucose readings directly on the reader device.
For those paying entirely out-of-pocket, the Freestyle Libre 3 provides significant budget relief. Even with insurance, the Libre 3 has much lower copays given its retail price point. Cost should not be a limiting factor for accessing CGM technology with the introduction of the Libre 3.
The affordable innovation of the Libre 3 opens up CGMs to a wider population. People with high deductible health plans or uncovered medical costs can now consider CGM technology. Cost savings with the Libre 3 make it the most budget-friendly CGM option.
The Freestyle Libre 3 is likely to be covered by most insurance plans that currently cover CGMs like the Freestyle Libre 2, Dexcom G6, etc. However, the specifics may vary depending on your insurance provider, plan type, and deductible status.
Most private insurance plans and Medicare cover some portion of CGM costs, though coverage levels differ. Medicaid also offers varying CGM coverage depending on your state. Here are some things to know about potential insurance coverage for Libre 3:
The best approach is to call your insurer directly and ask about your plan’s current and future coverage for the Freestyle Libre 3. This will give you the most accurate picture of potential out-of-pocket costs. Be sure to get any information in writing for future reference.
The Freestyle Libre 3 is still a new product, so details on financial assistance programs are still emerging. However, based on existing programs for the Libre 2 and insights from Abbott, we can expect the following types of financial assistance for the Libre 3:
Abbott Financial Assistance: Abbott currently offers financial assistance for the Libre 2 to help uninsured and underinsured patients access the CGM system at little or no cost. The details of the Libre 3 financial assistance program have not been announced yet, but Abbott will likely extend a similar program to the Libre 3. This will help eligible patients get the Libre 3 reader and sensors for free or low cost based on their income level and insurance status.
Co-Pay Reduction Cards: Abbott also provides co-pay reduction cards that lower the out-of-pocket costs for insured patients. For the Libre 2, the card lowers costs to no more than $10 per sensor. It’s reasonable to expect a similar co-pay card will be available for Libre 3 users to make their co-insurance affordable.
Medicare Coverage: Medicare provides coverage for some CGMs for patients who meet glucose testing requirements. Libre 2 is currently covered for some Medicare beneficiaries under certain conditions. Likely, Libre 3 will also eventually have Medicare coverage, but details are still pending.
Other Assistance Programs: There are various other nonprofit organizations and assistance funds that can provide financial aid for medical devices and supplies. These include national groups like JDRF as well as more local and regional assistance funds. Patients can research what programs are available in their area that could potentially help them afford Libre 3.
As more information is released on Libre 3 pricing and access leading up to the launch, we should learn more about the financial assistance programs that can help patients afford this new CGM. Abbott seems committed to making the technology accessible, even for customers with limited incomes and insurance coverage.
The Freestyle Libre 3 launched first in Europe in late 2022 before being approved for the US market. As a result, international pricing for the Libre 3 gives us an indication of what to expect in other countries once it becomes available.
In the UK, the Freestyle Libre 3 is priced similarly to the previous Libre 2 model. Sensors cost around £50 per month for direct cash purchases. With the National Health Service (NHS) in England covering Libre sensors for certain patients like children or those on insulin pumps, many users can access the Libre 3 at no upfront cost.
Pricing in Canada is comparable at around CAD $70-90 per sensor, with coverage varying by province. Some provinces like Ontario provide funding assistance programs to make CGMs affordable for type 1 diabetes patients.
In Australia, the Libre 3 will retail for about AU $70 per sensor. While not currently subsidized under the national health plan, CGMs like the Libre are eligible for government rebates that reduce the out-of-pocket cost. Many Australians can access the Libre for under AU $40 per month.
Based on current Libre 2 pricing in these regions, we can expect the Libre 3 to be priced similarly in the range of $50-90 per sensor. With government subsidies, insurance coverage, and financial assistance in many countries, the affordability of this next-gen CGM should continue improving access for more patients globally.
The Freestyle Libre 3 is a brand-new CGM that was just FDA-approved in January 2023. As with most new medical devices and technologies, the pricing is often high initially after launch. However, several factors point to the potential for lower costs over time.
First, as Abbott gains more experience manufacturing and distributing the Libre 3 at scale, they may be able to achieve greater efficiencies and discounts on components that allow them to reduce the price. Many technology products see price declines over time.
Second, the competitive environment may drive down costs. The Libre 3 will compete with existing CGMs like the Dexcom G6 and new products from competitors. If other companies can offer similar capabilities at lower prices, it may force Abbott to drop the pricing on the Libre 3 to stay competitive. The rival Dexcom G7 is expected to launch in 2023 and may be priced aggressively.
Lastly, as more patients adopt CGM technology as the Libre 3 and insurance coverage expands, the larger patient pool and reimbursements can enable the manufacturer to reduce costs. With a bigger customer base using CGMs, Abbott can spread out the R&D and production costs over more units.
In summary, while the launch price of the Freestyle Libre 3 is still being determined, several market dynamics around growing adoption, competition, and manufacturing efficiencies point to the potential for lower long-term costs for this new CGM. But the actual decline in pricing may depend on how the competitive landscape evolves. Patients should watch closely for any discounts or lower-cost options that become available.
The Freestyle Libre 3 offers the potential for significant cost savings for people with diabetes in the long run. While the upfront cost of the Libre 3 sensors may seem high, the value comes from the health benefits and potential medical costs avoided by using this new CGM system consistently.
The Libre 3 has features that can help diabetics better manage their blood sugar. The 14-day sensor means fewer finger sticks to test blood glucose levels. The real-time alarms for highs and lows allow faster response to glycemic events. And the Bluetooth connectivity provides seamless glucose data tracking. All of these capabilities may help users improve their A1C levels over time with disciplined use.
Studies have shown that improved A1C levels from CGM use can reduce the risk and severity of diabetes complications. This includes a reduction in heart disease, stroke, kidney disease, nerve damage, vision issues, and amputations. The costs involved with treating these complications are extremely high, so avoiding or delaying them leads to significant medical cost savings. One analysis showed A1C reduction from 9% to 7% could save between $4,000 to $10,000 per patient annually.
Beyond the direct medical savings, better blood glucose management improves overall health and quality of life. This allows people with diabetes to miss fewer days of work/school due to illness. It also increases energy levels and lifespan since diabetes complications are avoided or delayed. While difficult to quantify, these benefits are real and provide meaningful value to Libre 3 users.
In summary, the upfront price of Freestyle Libre 3 sensors is an investment that can lead to better health outcomes and significant cost savings in both the near and long-term future. For people with diabetes looking to optimize blood sugar control, the value far exceeds just the sticker price.
The new Freestyle Libre 3 continuous glucose monitor (CGM) offers some potential advantages over prior versions, including a fully disposable sensor, 14-day wear time, and optional real-time alarms. However, the biggest question for many prospective users is “How much will the Libre 3 cost me?”
Key takeaways on expected Libre 3 pricing:
Given that glucose monitoring is a medical necessity for diabetics, it’s promising that Libre 3 introductory pricing stays consistent with the previous version. Widespread access and affordability will be key for this life-improving technology. As a new product, longer-term effects on pricing remain to be seen. For now, most users should be able to upgrade to Libre 3 without a major impact on their budgets. Overall, competitive pricing and financial assistance programs reflect a commitment to access over profits.
Sign up to receive our email, delivering the latest stories straight to your inbox.
